Concord Drugs Peer Comparison

BSE: 538965

₹81.92

₹1.30 (1.61%)

As on 01-Sep-2026IST

Market cap

₹108 Cr

Revenue (TTM)

₹86 Cr

P/E Ratio

52.6

P/B Ratio

2.2

Div. Yield

0 %

Edit

	Concord Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Market cap (₹ Cr)	108	21,330	20,606	17,990	17,318
Revenue (₹ Cr)	86	2,570	2,287	3,230	2,432
Net Profit (₹ Cr)	2.05	735.15	678.07	666.92	169.62
Net Margin (%)	2.38	26.88	28.10	20.60	6.90
RoE (%)	4.94	19.16	19.73	18.75	20.76
Price to Earnings	52.62	29.01	30.97	27.94	102.10
Price-To-Book	2.17	4.84	5.47	4.45	19.15

Income Statement (₹ Cr)

	Concord Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Operating Revenue	83.40	2,569.77	2,287.33	3,229.67	2,432.06
Total Income	83.40	2,735.39	2,413.29	3,237.12	2,458.54
Total Expenditure	77.83	1,628.14	1,490.75	2,090.06	2,202.20
EBITDA	5.57	941.63	796.58	1,139.61	229.86
Depreciation	1.34	57.58	78.10	281.06	17.24
EBIT	4.23	884.05	718.48	858.55	212.62
Interest	1.39	7.69	0.88	190.64	5.72
Other Income	0.00	165.62	125.96	7.45	26.48
Exceptional Items	0.00	-49.16	0.00	-17.24	-5.13
Profit before Tax	2.84	992.82	843.56	658.12	228.25
Provision for Tax	0.80	257.67	165.49	-8.80	58.63
Profit after Tax	2.04	735.15	678.07	666.92	169.62

	Concord Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Shareholder's Funds	48.51	4,202.90	3,586.42	3,902.67	872.79
Minority Interest	0.00	0.00	-12.71	-21.81	0.00
Non-Current Liabilities	5.32	91.50	28.74	1,392.75	134.50
Current Liabilities	18.02	627.48	385.94	2,077.10	981.81
Total Liabilities	--	4,911.11	3,207.85	6,862.28	1,879.19

	Concord Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Non-Current Assets	15.68	770.28	1,291.22	5,617.77	42.47
Current Assets	49.47	3,803.22	2,585.66	1,539.85	1,739.93
Total Assets	--	4,911.11	3,207.85	6,862.28	1,879.19
Total Debt*	--	2.50	0.55	2,421.66	0.00
Net Current Assets	31.45	3,175.74	2,199.72	-537.25	758.12
Contingent Liabilities	--	363.79	0.64	64.29	98.41

	Concord Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Cash From Operating Activities	--	659.75	432.37	1,065.01	65.36
Cash Flow from Investing Activities	--	-71.34	-334.73	-79.97	30.80
Cash from Financing Activities	--	-205.34	-38.32	-881.32	-65.59
Net Cash Inflow / Outflow	--	383.07	59.32	103.72	30.57

	Concord Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
ROCE (%)	--	26.21	26.22	13.59	21.29
ROE (%)	4.91	19.16	19.73	18.75	20.76
ROA (%)	3.12	14.95	18.69	9.26	9.67
EBIT Margin (%)	5.07	34.40	31.41	26.58	8.74
Net Margin (%)	2.44	26.88	28.10	20.60	6.90
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Concord Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Revenue Growth (%)	89.63	10.69	15.01	9.59	31.10
EBIT Growth (%)	66.56	24.14	18.45	16.84	-12.99
Net Profit Growth (%)	413.10	-9.09	19.61	62.68	-7.49
EPS Growth (%)	345.60	14.40	17.73	67.41	-18.33
Book Value Growth (%)	--	17.30	23.77	10.19	7.70

	Concord Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Price / Earnings	46.31	27.65	30.97	27.26	99.79
Price / Book Value	2.17	4.84	5.47	4.45	19.15
Dividend Yield (%)	0.00	1.61	0.15	0.56	0.52
EV/EBITDA	22.80	19.35	24.74	17.71	73.39
Market Cap (₹ Cr)	--	18,318.10	15,219.80	19,292.77	21,515.93

	Concord Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debt to Equity	0.04	0.00	0.00	0.24	0.00
Short term debt to equity ratio	--	0.00	0.00	0.14	--
Current Ratio	2.74	6.06	6.70	0.74	1.77
Quick Ratio	1.73	5.31	5.59	0.53	0.73
Interest Coverage	3.04	130.11	959.59	4.45	40.90

	Concord Drugs	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debtors to sales (%)	33.73	7.07	36.10	21.07	8.79
Asset Turnover	1.28	0.52	0.63	0.45	1.39
Receivable days	--	29.10	110.70	54.07	35.81
Inventory Days	--	69.53	65.86	32.16	82.25
Payable days	--	76.77	105.88	140.91	124.39
Cash Conversion Cycle	--	21.86	70.68	-54.68	-6.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.